Mayo Clinic, WuXi AppTec diagnostics joint venture to open first R&D center in the U.S.

test tubes
Previously, the WuXi Diagnostics joint venture aimed to co-develop and deliver clinical diagnostic services in China. (Pixabay)

WuXi Diagnostics, a joint venture launched last year by WuXi AppTec and Mayo Clinic, is planning to open its first U.S.-based R&D center just down the street from its benefactor in Rochester, Minnesota.

The facility, to be based in the new life sciences center One Discovery Square, is expected to open before the end of this year.

It will serve as a center of WuXi Diagnostics’ development of clinical diagnostic tests and will work in collaboration with Mayo’s department of laboratory medicine and pathology as well as its Advanced Diagnostics Laboratory.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

"Our new facility will directly contribute to our further cooperation with Mayo Clinic," WuXi Diagnostics CEO Jason Liu said in a statement. "It will leverage WuXi Diagnostics' research and development capability and Mayo Clinic's advanced clinical practice to accelerate esoteric diagnostic product development and to transform discoveries into diagnostic tests that will benefit all."

RELATED: WuXi opens CAR-T biomanufacturing facility in Philadelphia

Previously, the joint venture aimed to co-develop and deliver clinical diagnostic services in China.

"This facility allows us to further leverage our existing knowledge and expertise in the esoteric diagnostics in a wide range of areas–cancer, hematology, neurology, gastroenterology, genetics, to name just a few–to provide patients worldwide with laboratory testing that addresses their specific health care needs," said William Morice II, president of Mayo Clinic Laboratories and chair of laboratory medicine and pathology at Mayo Clinic.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.